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BACKGROUND
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heart123.com.

Coronary revascularization guided by fractional flow reserve (FFR) is associated
with better patient outcomes after the procedure than revascularization guided by
angiography alone. It is unknown whether the instantaneous wave-free ratio (iFR),
an alternative measure that does not require the administration of adenosine, will
offer benefits similar to those of FFR.

This article was published on March 18,
2017, at NEJM.org.

METHODS

N Engl J Med 2017;376:1824-34.
DOI: 10.1056/NEJMoa1700445
Copyright © 2017 Massachusetts Medical Society.

We randomly assigned 2492 patients with coronary artery disease, in a 1:1 ratio,
to undergo either iFR-guided or FFR-guided coronary revascularization. The primary
end point was the 1-year risk of major adverse cardiac events, which were a composite of death from any cause, nonfatal myocardial infarction, or unplanned revascularization. The trial was designed to show the noninferiority of iFR to FFR,
with a margin of 3.4 percentage points for the difference in risk.
RESULTS

At 1 year, the primary end point had occurred in 78 of 1148 patients (6.8%) in the
iFR group and in 83 of 1182 patients (7.0%) in the FFR group (difference in risk,
−0.2 percentage points; 95% confidence interval [CI], −2.3 to 1.8; P<0.001 for
noninferiority; hazard ratio, 0.95; 95% CI, 0.68 to 1.33; P = 0.78). The risk of each
component of the primary end point and of death from cardiovascular or noncardiovascular causes did not differ significantly between the groups. The number of
patients who had adverse procedural symptoms and clinical signs was significantly lower in the iFR group than in the FFR group (39 patients [3.1%] vs. 385
patients [30.8%], P<0.001), and the median procedural time was significantly
shorter (40.5 minutes vs. 45.0 minutes, P = 0.001).
CONCLUSIONS

Coronary revascularization guided by iFR was noninferior to revascularization
guided by FFR with respect to the risk of major adverse cardiac events at 1 year. The
rate of adverse procedural signs and symptoms was lower and the procedural time
was shorter with iFR than with FFR. (Funded by Philips Volcano; DEFINE-FLAIR
ClinicalTrials.gov number, NCT02053038.)
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F

or the past 20 years, physiological
measurements obtained during invasive procedures have been used to guide coronary
revascularization. Pioneering work supported the
use of flow measurements to make safe decisions
about revascularization,1,2 but this approach was
soon superseded by the use of fractional flow
reserve (FFR), which measures pressure as a surrogate of flow to estimate the severity of stenosis.3-5 FFR was successful largely because of its
technical simplicity and because clinical trials
showed that it was associated with improved
clinical outcomes after percutaneous coronary
intervention (PCI).6,7 Consequently, FFR is now
included in the appropriate-use criteria for coronary angiography and in the American College of
Cardiology–American Heart Association–European
Society of Cardiology guidelines; despite these
recommendations, its adoption remains limited.8-10
FFR must be measured during maximal hyperemia, which is typically induced with the administration of a potent intravenous or intracoronary
vasodilator, such as adenosine.11 Several studies
have questioned the need for the administration
of a vasodilator to assess stenosis severity.12-14 In
these studies, investigators found that in determining stenosis severity, FFR was not superior to
the instantaneous wave-free ratio (iFR), a pressurederived index of stenosis severity that is not obtained with the administration of a vasodilator.
We aimed to determine the efficacy and safety
of an iFR-guided strategy versus an FFR-guided
strategy for coronary revascularization.

Me thods
Trial Design and Management

DEFINE-FLAIR (Functional Lesion Assessment of
Intermediate Stenosis to Guide Revascularisation)
is a multicenter, international, randomized,
blinded trial in which iFR is being compared
with FFR for physiologically guided coronary
revascularization. The trial, which is ongoing, is
being performed at 49 interventional sites across
19 countries on 4 continents. The 1-year outcomes, on which the primary trial analysis is
based, are reported here.
The trial was designed by the steering committee (for a list of committee members, see the
Supplementary Appendix, available with the full
text of this article at NEJM.org). Central ethics
approval was granted by the National Research
Ethics Service Committee London, and local ethics
n engl j med 376;19

approval was granted at each participating site.
The trial is funded by an unrestricted educational grant from Philips Volcano, which had no
role in the design of the trial, the collection or
analysis of the data, the writing of the manuscript, or the decision to submit the manuscript
for publication.
Trial management and oversight were performed by personnel at the Imperial College
Trials Unit, Imperial College London, who maintained the clinical database and conducted all
the data analyses independent of the funder. A
risk assessment established that the trial was of
low risk to the patients; therefore, no data and
safety monitoring board was established. The
first draft of the manuscript was written by the
first author, and all the authors participated in
trial oversight, approved all subsequent drafts of
the manuscript, and made the decision to submit the manuscript for publication. The steering
committee and all the authors vouch for the accuracy and completeness of the data and analyses and for the fidelity of the study to the trial
protocol and statistical analysis plan, which are
available at NEJM.org.
Population

Patients who had undergone coronary angiography were assessed for trial eligibility. Patients
were eligible for inclusion in the trial if they had
coronary artery disease with at least one native
artery in which the stenosis was of questionable
physiological severity (typically, an artery with
40 to 70% stenosis of the diameter on visual assessment). Patients with tandem stenoses (i.e.,
stenoses separated by more than 10 mm within
a single vessel) that would require independent
evaluation and treatment were excluded. A full
list of inclusion and exclusion criteria is provided
in Table S1 in the Supplementary Appendix. No
exclusions were made on the basis of heart rate
or rhythm. Written informed consent was obtained from all the patients before their enrollment in the trial.
Randomization

Eligible patients were randomly assigned to undergo revascularization guided by either FFR or
iFR. Randomization was performed with the use
of an automated and validated online randomization tool (SRUB, Imperial College London).
During the trial procedures, investigators were
allowed to obtain FFR or iFR measurements only
nejm.org
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in accordance with group assignment. Verification
of the data was performed in each patient with
the use of the electronic physiology record,
which was uploaded directly from the physiological console for each patient into the electronic
clinical record (Fig. S1 in the Supplementary
Appendix). During the procedure, patients were
not told which technique was used for physiological assessment, and they remained unaware
of their group assignment throughout the entire
course of the trial. The research nurses and doctors who were responsible for the follow-up visits
were also unaware of the group assignments.
Procedure

Before the FFR or iFR measurement was obtained, intracoronary nitrates were administered
to control vasomotor tone. The physiological
measurements were obtained in the routine
manner with the use of a coronary-pressure
guidewire (Philips Volcano) (Figs. S1 and S2 in
the Supplementary Appendix). Physiological assessment was performed in all vessels with questionable stenosis severity. In patients with an
acute coronary syndrome, physiological assessment was performed in only nonculprit vessels,
after the culprit vessel had been revascularized.
Prespecified treatment thresholds were an FFR of
0.80 and an iFR of 0.89 (Fig. S3 in the Supplementary Appendix). When the FFR or iFR for a
given stenosis was equal to or lower than the
prespecified threshold, the stenosis was revascularized with a drug-eluting stent or a bioresorbable vascular scaffold or by coronary-artery bypass grafting (CABG). When the FFR or iFR was
higher than the prespecified threshold, treatment
was deferred. When multivessel revascularization was attempted, investigators could choose
to prespecify a staged treatment plan, with the
staged procedure performed within 60 days. Adverse procedural signs and symptoms were documented.
Routine clinical follow-up assessments were
performed at 30 days and at 1 year, and followup by telephone was conducted at 6 months.
Complete monitoring of every electronic clinical
record was performed, and the data were confirmed by on-site source-document verification
in a randomly selected 30% of patients.

of
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posite of death, nonfatal myocardial infarction,
or unplanned revascularization. Death was considered to be from cardiovascular causes unless
an unequivocal noncardiovascular cause was established. Myocardial infarction was classified
as either spontaneous or periprocedural and as
either ST-segment elevation myocardial infarction
(STEMI) or non-STEMI (NSTEMI). Revascularization was considered to be unplanned when it was
not the index procedure and was not identified
at the time of the index procedure as a staged
procedure to occur within 60 days. Detailed endpoint definitions, which did not change after the
commencement of the trial, are provided in the
Supplementary Appendix.
End-point events were adjudicated with the use
of anonymized source documentation by a committee of international experts who were not
part of the steering committee. A consensus
decision was made on the basis of prespecified
end-point definitions. Members of the events
committee remain unaware of the identities of
the patients and their group assignments.
Statistical Analysis

The prespecified trial hypothesis was that iFR
would be noninferior to FFR with respect to the
risk of major adverse cardiac events at 1 year
among patients undergoing physiologically guided revascularization. We based the sample size
on an assumed annual rate of primary end-point
events of 8.5% in a population that includes a
mix of patients with either stable coronary disease or acute coronary syndromes15; given this
rate, we calculated that a sample size of 2305
patients would provide the trial with 90% power
to detect the noninferiority of iFR to FFR, with
the use of a noninferiority margin of 3.4 percentage points for the difference in risk, at a type I
error rate of 5%. To allow for attrition, the target
sample size was set at 2500 patients.
Both a risk-difference analysis and a time-toevent analysis were performed. The time-to-event
analysis was conducted with the use of the
Kaplan–Meier method. A Cox survival model
was used to derive hazard ratios. For the results
of both analyses, two-sided 95% confidence intervals (whose upper limits correspond to the
upper limits of one-sided 97.5% confidence intervals) and two-sided 99% confidence intervals
End Points
(whose upper limits correspond to the upper
The primary end point was the 1-year risk of limits of one-sided 99.5% confidence intervals)
major adverse cardiac events, which were a com- are reported. The validity of the proportional1826
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2535 Patients were assessed for eligibility

43 Were excluded
39 Did not meet the inclusion criteria
4 Were unwilling to participate

2492 Underwent randomization

1242 Were assigned to the iFR group
1234 Underwent iFR-guided assessment
8 Underwent FFR-guided assessment

1250 Were assigned to the FFR group
1245 Underwent FFR-guided assessment
5 Underwent iFR-guided assessment

95 Were withdrawn from the
study before or at 1 yr
7 Had protocol violations

71 Were withdrawn from the
study before or at 1 yr
6 Had protocol violations

1147 Were included in the intention-to-treat analysis
1140 Were included in the per-protocol analysis

1179 Were included in the intention-to-treat analysis
1173 Were included in the per-protocol analysis

Figure 1. Enrollment, Randomization, Follow-up, and Analysis.
FFR denotes fractional flow reserve, and iFR instantaneous wave-free ratio.

hazards assumption was tested with Schoenfeld
residuals. There were no signs of violation of the
proportional-hazards assumption.
Patients who withdrew from the study before
they reached 1 year of follow-up and who were
event-free at their last visit were excluded from
the risk-difference analysis for the primary end
point and its components. Data for these patients were censored at the time of withdrawal
for the time-to-event analysis. Patients who had
a myocardial infarction or an unplanned revascularization before withdrawing from the study
were included in the risk-difference analysis.

R e sult s
Patients and Procedures

During the recruitment period (January 2014 to
December 2015), a total of 2535 patients who
underwent coronary angiography were assessed
for trial eligibility. Of the 2492 patients who met
the enrollment criteria, 1242 were assigned to the
iFR group and 1250 to the FFR group (Fig. 1).
The baseline demographic characteristics of the
patients are shown in Table 1. The mean age of
the patients was 65 years, 76% were men, and
80% had stable coronary artery disease.
n engl j med 376;19

Procedural characteristics for the two trial
groups are shown in Figure 1 and Table 2. A
total of 99.4% of the patients assigned to the iFR
group and 99.6% of those assigned to the FFR
group underwent the assigned procedure. Crossover, which represented a deviation from the
protocol, occurred in 13 cases and was due to
profound early adenosine-induced bradycardia and
hypotension in 1 case and to site errors in the
remaining 12 cases. There were no cases in which
heart-rhythm disturbances or lack of electrocardiographic assessment prevented FFR or iFR
measurements from being obtained.
The number of vessels evaluated did not differ significantly between the iFR group and the
FFR group (total number assessed, 1575 and
1608, respectively; mean [±SD] number evaluated
per patient, 1.27±0.61 and 1.29±0.63; P = 0.58).
The mean iFR and FFR measurements were close
to their respective thresholds (mean iFR, 0.91±0.09;
mean FFR, 0.83±0.09); these findings suggest
that most of the assessed vessels had stenosis of
intermediate severity (Figs. S4 and S5 in the
Supplementary Appendix). The number of functionally significant stenoses (i.e., stenoses with
an iFR or FFR below the treatment threshold) was
significantly lower in the iFR group than in the
nejm.org
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Table 1. Baseline Characteristics of the Patients.*
Characteristic
Age — yr
Sex — no. (%)
Female
Male
Disease type — no. (%)†
STEMI
Acute coronary syndrome
Stable disease
Diabetes — no. (%)
Non–insulin dependent
Insulin dependent
Smoking status — no. (%)
Former smoker
Current smoker
Hypertension — no. (%)
Hypercholesterolemia — no. (%)
Previous myocardial infarction — no. (%)
Previous percutaneous coronary intervention — no. (%)
Previous heart condition — no. (%)
Congestive heart failure — no. (%)
NYHA class — no. (%)‡
I
II
III
IV
Impairment of left ventricular function — no. (%)
Mild
Moderate
Severe
CCS angina class — no. (%)§
I
II
III
IV
Systolic blood pressure — mm Hg
Diastolic blood pressure — mm Hg
Heart rate — beats/min
Body-mass index¶
Total cholesterol — mmol/liter
Hemoglobin — mg/dl
Creatinine — mmol/liter

iFR Group
(N = 1242)

FFR Group
(N = 1250)

65.5±10.8

65.2±10.6

280 (22.5)
962 (77.5)

321 (25.7)
929 (74.3)

49 (3.9)
186 (15.0)
986 (79.4)

42 (3.4)
184 (14.7)
1012 (81.0)

288 (23.2)
94 (7.6)

282 (22.6)
94 (7.5)

461 (37.1)
243 (19.6)
873 (70.3)
794 (63.9)
358 (28.8)
489 (39.4)
489 (39.4)
77 (6.2)

443 (35.4)
262 (21.0)
884 (70.7)
792 (63.4)
376 (30.1)
527 (42.2)
530 (42.4)
67 (5.4)

21 (1.7)
28 (2.3)
16 (1.3)
1 (0.1)

13 (1.0)
32 (2.6)
14 (1.1)
3 (0.2)

147 (11.8)
65 (5.2)
23 (1.9)

150 (12.0)
58 (4.6)
27 (2.2)

347 (27.9)
374 (30.1)
127 (10.2)
81 (6.5)
133.9±20.3
74.9±11.9
68.9±12.6
27.8±5.0
4.1±1.0
13.9±1.6
90.2±62.0

305 (24.4)
370 (29.6)
154 (12.3)
72 (5.8)
134.3±20.1
75.0±11.8
69.1±12.8
27.5±5.0
4.1±0.9
13.8±1.6
93.2±81.1

*	Plus–minus values are means ±SD. There were no significant differences between the two groups in baseline characteristics. To convert the values for cholesterol to milligrams per deciliter, divide by 0.02586. FFR denotes fractional flow
reserve, iFR instantaneous wave-free ratio, and STEMI ST-segment elevation myocardial infarction.
†	In patients with STEMI or an acute coronary syndrome, only nonculprit lesions were evaluated. Patients with STEMI were
evaluated more than 48 hours after the event occurred.
‡	In the New York Heart Association (NYHA) functional classification system, classes range from I to IV, with higher classes
indicating greater limitations of physical activity owing to heart disease.
§	In the Canadian Cardiovascular Society (CCS) functional classification system, classes range from I to IV, with higher
classes indicating greater limitations of physical activity owing to angina.
¶	The body-mass index is the weight in kilograms divided by the square of the height in meters.
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FFR group (451 vs. 557 [28.6% vs. 34.6% of total
vessels evaluated], P = 0.004).
In both the iFR group and the FFR group, the
number of patients who underwent PCI (565 and
625, respectively) was greater than the number
who had functionally significant stenoses (426
and 486, respectively). This is because PCI procedures that were performed in culprit vessels of
patients with an acute coronary syndrome and in
angiographically significant stenoses (neither of
which required physiological assessment) were
included in the totals. The median procedure
time was significantly shorter in the iFR group
than in the FFR group (40.5 minutes [interquartile range, 27.0 to 60.0] vs. 45.0 minutes [interquartile range, 30.0 to 66.0], P = 0.001).
Outcomes

At 1 year, the primary end point (a composite of
major adverse cardiac events) had occurred in 78
of 1148 patients (6.8%) in the iFR group and in
83 of 1182 patients (7.0%) in the FFR group
(Fig. 2). The hazard ratio was 0.95 (95% confidence interval [CI], 0.68 to 1.33; P = 0.78), and
the difference in risk was −0.2 percentage points
(95% CI, −2.3 to 1.8; 99% CI, −2.9 to 2.5;
P = 0.83) (Table 3, and Table S2 in the Supplementary Appendix). The upper limits of the twosided 95% and 99% confidence intervals were
within the prespecified noninferiority margin of
3.4 percentage points (P<0.001 for noninferiority). The risks of each individual component of
the primary end point and of death from cardiovascular or noncardiovascular causes did not
differ significantly between the two groups.
The noninferiority of iFR to FFR was also
confirmed in the per-protocol analysis (Tables
S4 and S5 in the Supplementary Appendix). In
the per-protocol analysis, the hazard ratio for
major adverse cardiac events was 0.94 (95% CI,
0.67 to 1.31; P = 0.72), and the difference in risk
was −0.3 percentage points (95% CI, −2.4 to 1.8;
99% CI, −3.0 to 2.4; P = 0.77). The risk of each
individual component of the composite end point
did not differ significantly between the two
groups in the per-protocol analyses.
Procedural Signs and Symptoms

In the iFR group, 39 patients (3.1%) reported
adverse procedural symptoms or signs, including 19 who reported chest pain and 13 who reported dyspnea (Table 2). In the FFR group, 385
n engl j med 376;19

patients (30.8%) reported adverse procedural
symptoms or signs, including 250 who reported
dyspnea and 90 who reported chest pain. The
difference between the two groups in the number of patients with adverse procedural symptoms or signs was significant (P<0.001) (Fig. S9
in the Supplementary Appendix). Serious adverse
events (bronchospasm and ventricular arrhythmias) were reported in 8 patients in the FFR
group (after hyperemia) and in 1 patient in the
iFR group.

Discussion
In the DEFINE-FLAIR trial, we found that iFRguided coronary revascularization was noninferior to FFR-guided revascularization with respect
to the risk of major adverse cardiac events. The
use of iFR was also associated with a lower rate
of procedural signs and symptoms and with a
shorter procedural time than the use of FFR.
There were no significant differences between
the trial groups in the rates of death from any
cause, death from cardiovascular causes, nonfatal myocardial infarction, and unplanned revascularization. These results suggest that the
benefits of physiologically guided coronary revascularization with FFR can also be achieved
with iFR. Our principal findings are similar to
those now reported in the Journal by Götberg
et al.16
It has previously been proposed that a hybrid
iFR–FFR approach might be advantageous for
the detection of functionally significant stenoses, with iFR used as the initial measure and
FFR used only to evaluate stenoses that were of
intermediate severity on iFR-guided assessment.17,18 However, the results of our trial suggest that iFR alone can effectively identify stenoses that require intervention. Our trial also
provides clinical evidence that there is no significant advantage to the administration of a
hyperemic agent — a finding consistent with
results of studies in which iFR and FFR were
compared with other reference standards.13,14,19,20
Although evidence supporting the benefits of
physiologically guided revascularization has accumulated over the past decade, adoption of this
approach in clinical practice has lagged. There
are many reasons for this, including equipment
and drug costs, inadequate reimbursement, physician preferences, patient symptoms, and addinejm.org
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Table 2. Procedural Characteristics.*
Variable

iFR Group
(N = 1242)

FFR Group
(N = 1250)

P Value†

Radial-artery approach — no. of patients (%)

896 (72.1)

888 (71.0)

0.54

40.5

45.0

0.001

27.0–60.0

30.0–66.0

Total

NA

1608 (100)

Intracoronary adenosine

NA

455 (28.3)

Intravenous adenosine

NA

950 (59.1)

Other agent

NA

203 (12.6)

505 (40.7)

519 (41.5)

Procedure time — min
Median
Interquartile range
Hyperemic agent administered — no. of patients (% of total no. who
received a hyperemic agent)

Multivessel disease — no. of patients (%)

0.66

Type of vessel evaluated — no. (% of total vessels evaluated)‡
Total

1575 (100)

1608 (100)

0.58

Left anterior descending artery

844 (53.6)

845 (52.5)

0.56

Left circumflex artery

323 (20.5)

333 (20.7)

0.89

Right coronary artery

374 (23.7)

393 (24.4)

0.65

33 (2.1)

31 (1.9)

0.74

1 (0.1)

6 (0.4)

0.06

1879

1940

0.42

Other
Unknown
Total no. of vessels evaluated or treated‡
No. of vessels evaluated or treated per patient‡

1.51±0.76

1.55±0.80

0.42

Functionally significant lesions — no. (% of total vessels evaluated)§

451 (28.6)

557 (34.6)

0.004

≥1 Functionally significant lesions present — no. of patients (%)§

426 (34.3)

486 (38.9)

0.02

Mean iFR

0.91±0.09

NA

Mean FFR

NA

0.83±0.09

<0.60

NA

1.96

0.60–0.90

NA

75.08

>0.90

NA

22.96

Total

590 (47.5)

667 (53.4)

0.003

CABG

25 (2.0)

42 (3.4)

0.04

565 (45.5)

625 (50.0)

0.02

Total

822 (100)

906 (100)

0.86

Drug-eluting stent

811 (98.7)

893 (98.6)

11 (1.3)

13 (1.4)

0.66±0.92

0.72±0.96

0.09

28.0

28.0

0.74

18.0–42.0

18.0–44.0

Percent of lesions within the FFR range

Revascularization performed — no. of patients (%)

PCI
Stents placed — no. (% of total stents placed)

Bioresorbable vascular scaffold
No. of stents placed per patient
Stent length per patient — mm
Median
Interquartile range
Stent diameter — mm
Median
Interquartile range

1830
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3.00

2.67–3.25

2.75–3.25

0.44
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Table 2. (Continued.)
Variable

iFR Group
(N = 1242)

FFR Group
(N = 1250)

P Value†

Stents placed with postdilation — no. (% of total stents placed)

407 (49.5)

425 (46.9)

0.28

PCI procedures performed with pressure wire — no. (% of total
stents placed)

261 (31.8)

278 (30.7)

0.63

Patient-reported adverse procedural symptoms or signs
— no. of patients (%)

39 (3.1)

385 (30.8)

<0.001

Patient-reported dyspnea — no. of patients (%)

13 (1.0)

250 (20.0)

Patient-reported chest pain — no. of patients (%)

19 (1.5)

90 (7.2)

Heart-rhythm disturbance

2 (0.2)

60 (4.8)

Significant hypotension

4 (0.3)

13 (1.0)

Vomiting or nausea

1 (0.1)

11 (0.9)

Ventricular arrhythmia or bronchospasm¶

1 (0.1)

8 (0.6)

Other

4 (0.3)

38 (3.0)

Physician-reported adverse procedural signs — no. of patients (%)

*	Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. CABG denotes coronary-artery
bypass grafting, NA not applicable, and PCI percutaneous coronary intervention.
†	P values that compare distributions were calculated by means of the Wilcoxon rank-sum test. P values that compare
percentages were calculated by means of a test for proportions.
‡	Evaluated vessels are vessels that underwent physiological assessment. Treated vessels are vessels that underwent PCI.
§	Functionally significant lesions are lesions with an iFR or FFR equal to or lower than the treatment threshold (0.89 and
0.80, respectively).
¶	Serious adverse events included ventricular arrhythmias and bronchospasm; one case of ventricular arrhythmia occurred
in the iFR group, and one case of ventricular arrhythmia and seven cases of bronchospasm occurred in the FFR group.

Table 3. Outcomes for Difference in Risk at 1 Year.*
Outcome

iFR Group

FFR Group

Difference in Risk

P Value

percentage points
(95% CI)

percentage points
(99% CI)

83/1182 (7.0)

−0.2 (−2.3 to 1.8)†

−0.2 (−2.9 to 2.5)

0.83

no./total no. (%)
Primary end point: death from any cause,
nonfatal myocardial infarction, or
unplanned revascularization

78/1148 (6.8)

Unplanned revascularization

46/1147 (4.0)

63/1181 (5.3)

−1.3 (−3.0 to 0.4)

−1.3 (−3.1 to 1.9)

0.13

Nonfatal myocardial infarction

31/1148 (2.7)

28/1180 (2.4)

0.3 (−1.0 to 1.6)

0.3 (−1.4 to 2.0)

0.62

Death from cardiovascular causes

7/1147 (0.6)

4/1179 (0.3)

0.3 (−0.3 to 0.8)

0.3 (−0.5 to 1.0)

0.34

Death from noncardiovascular causes

15/1147 (1.3)

9/1179 (0.8)

0.5 (−0.3 to 1.4)

0.5 (−0.5 to 1.6)

0.19

Death from any cause

22/1147 (1.9)

13/1179 (1.1)

0.8 (−0.2 to 1.8)

0.8 (−0.5 to 2.1)

0.11

*	Patients who had a myocardial infarction or an unplanned revascularization before withdrawing from the study were included in the analyses.
†	For the primary end point, the upper limit of the 95% confidence interval was 1.8 percentage points, which was within the prespecified noninferiority margin of 3.4 percentage points.

tional procedural burden. Although adenosine is
a generally safe drug that is used in millions of
diagnostic procedures annually, its risks are well
documented21,22 and it is not suitable for every
patient; therefore, avoiding the use of adenosine
is preferable.11,23,24 In addition, adenosine contributes substantially to the cost of physiological
n engl j med 376;19

stenosis assessment, and its use is hampered in
many countries because it is unavailable or not
indicated for this purpose. Thus, the ability to
perform physiological assessments of coronaryartery stenoses without the use of adenosine
may increase the use of such assessments in
clinical practice.
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Figure 2. Cumulative Risk of the Primary End Point.
Shown is the cumulative risk of the composite of death from any cause,
nonfatal myocardial infarction, or unplanned revascularization at 1 year.
The inset shows the same data on an enlarged y axis.

Although the patients were not informed of
their group assignments, adverse procedural
symptoms or signs occurred in 30.8% of the
patients in the FFR group, as compared with
3.1% of the patients in the iFR group. This difference is most likely due to the side effects of
adenosine. It is therefore possible that at least
some patients in the FFR group became aware of
their group assignment. Such unblinding could
have led to bias in the rates of unplanned revascularization, especially if patients discussed these
symptoms with their physicians.
The number of functionally significant stenoses was lower in the iFR group than in the FFR
group. This difference could be a consequence
of dissimilar thresholds for the two measures.
In addition, iFR has been shown to be more
closely linked to coronary flow reserve than
FFR, and a previous study has shown higher
revascularization rates associated with assessment guided by FFR than with assessment
guided by coronary flow reserve.25 Regardless of
the explanation, the results of our trial suggest
that the use of iFR can lead to outcomes similar
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to those associated with FFR and to the placement of fewer (potentially unnecessary) stents.
The clinical population in our trial differed
from the population in the FAME trial (Fractional
Flow Reserve Versus Angiography for Multivessel
Evaluation), in which all the patients had multivessel disease and were scheduled for revascularization.6 In DEFINE-FLAIR, only 41% had multivessel disease. Although the benefit of coronary
revascularization in patients with single-vessel
disease is likely to be more uncertain, our trial
population is probably similar to the population
that would be seen in current clinical practice.
Given the clinical evidence in support of physiologically guided revascularization, it was considered unethical to repeat a study similar to
FAME, in which iFR-guided revascularization was
compared with angiography-guided revascularization.
In our trial, the noninferiority margin for the
difference in risk was set at 3.4 percentage
points, which meant that the upper limit of the
hazard ratio could have been as high as 1.40
while still allowing a claim of noninferiority.
Although this noninferiority margin is wide, it is
similar to margins used in other major clinical
trials in cardiology.26-32 The event rates were
lower than had been expected, because the number of patients with an acute coronary syndrome
who were enrolled in the trial was lower than had
been anticipated. However, when we used the prespecified noninferiority margin to test the actual event rate among the prespecified number
of patients, we found that iFR was noninferior to
FFR even when the upper limit of a one-sided
99.5% confidence interval was used.
In conclusion, we found that coronary revascularization guided by iFR was noninferior to revascularization guided by FFR with respect to
major adverse cardiac events at 1 year. The rate
of adverse procedural signs or symptoms was
lower and the procedure time was shorter in the
iFR group than in the FFR group.
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